Actively Recruiting
Study of 68Ga-JH12 PETCT Imaging to Assess Safety and Radiation Dosage in Adults with Various Solid Tumors
Led by First Affiliated Hospital of Fujian Medical University · Updated on 2024-11-14
5
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying 68Ga-JH12, a new radiotracer that targets the CXCR4 receptor, which is commonly found in various malignant tumors. This early phase 1 trial aims to assess the safety, distribution in the body, and radiation dose of 68Ga-JH12 in patients with different types of cancer. Previous studies showed that CXCR4 levels are linked to tumor growth, and 68Ga-JH12 has demonstrated stability and selective tumor accumulation in preclinical tests. Participants will receive an intravenous dose of 68Ga-JH12 ranging from 148 to 222 MBq. Dynamic PET scans will be performed at multiple time points after injectionstarting at 3 minutes and continuing through 150 minutesto observe how the tracer travels and accumulates in normal organs and tumors. This imaging process helps evaluate the tracers dosimetric properties. During the study, participants will be monitored for safety and tolerability for up to one week following tracer administration. Researchers will collect data on how the tracer distributes and the radiation it delivers to normal tissues and tumors. This study is expected to continue until the end of 2025, and participants will undergo scheduled PET imaging and safety assessments as part of their involvement.
CONDITIONS
Brief Title
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
Research Team
W
Weibing Miao, MD
G
Guochang Wang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
